Suven to present at 11th Clinical Trials on Alzheimer's Disease during October 24-27, 2018 - Barcelona, Spain
Deepthi | Myequity news | Date : 23-10-2018 10:50:00 IST
Suven Life Sciences is participating and presenting the baseline patient demographics and scales from the ongoing phase-2a proof-of-concept trial of SUVN-502 for moderate Alzheimer’s Disease at 11TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) during October 24-27, 2018 at BARCELONA, SPAIN
SUVN-502 is a promising pure, 5-HT6 receptor antagonist in development for the treatment of moderate Alzheimer’s disease, a novel triple combination treatment approach. This trial evaluates the efficacy and safety of SUVN-502 added to background stable donepezil and memantine, a triple therapy in subjects with moderate AD dementia. About Suven Life Sciences:
At CTAD, Suven is presenting the baseline patient demographics and scales from the ongoing phase-2a proof-of-concept trial of SUVN-502 for moderate Alzheimer’s disease. Top-line efficacy results from this study are expected during August/September of 2019
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets. Suven has 4 clinical stage compounds, a Phase 2 undergoing SUVN-502, Phase 2 ready SUVN-G3031, Phase 1 completed SUVN-D4010, Phase 1 commenced SUVN-911 and Phase 1 ready SUVN-I6107. In addition to these clinical compounds the Company has nine (9) internally-discovered therapeutic drug candidates currently in various stages of pre-clinical development targeting conditions such as ADHD, dementia, depression, Huntington’s disease, Parkinson’s disease and pain.